November 11, 2020Open Access

Venous Thromboembolism Risk With JAK Inhibitors: A Meta‐Analysis

MYMark YatesIthaka Harbors AMAmanda MootooKing's College London MAMaryam AdasThe King's College

Key Points

Key points are not available for this paper at this time.

Abstract

This meta-analysis of RCT data defines the VTE risk with JAK inhibitors as a class in IMID patients. The pooled IRRs do not provide evidence that support the current warnings of VTE risk for JAK inhibitors. These findings will aid continued development of clinical guidelines for the use of JAK inhibitors in IMIDs.

KI fragen

Bookmark

View Full Paper

Cite This Study

Yates et al. (Wed,) studied this question.

synapsesocial.com/papers/69d850c0f4e559c61eae36ec https://doi.org/https://doi.org/10.1002/art.41580

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Risk of venous thromboembolism in immune-mediated inflammatory diseases: a UK matched cohort study2020 · 36 citations
2Class II cytokine receptors and their ligands: Key antiviral and inflammatory modulators2003 · 266 citations
3Use of Glucocorticoids and Risk of Venous Thromboembolism: A Nationwide Population-Based Case-Control Study2013 · 40 citations
4The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double‐blind, placebo‐controlled phase IIa trial of three dosage levels of CP‐690,550 versus placebo2009 · 544 citations
5The efficacy and safety of tofacitinib in Asian patients with moderate to severe chronic plaque psoriasis: A Phase 3, randomized, double-blind, placebo-controlled study2017 · 87 citations

KI fragen

Bookmark

View Full Paper